RNA interference treatment in primary hyperoxaluria type 1

被引：0
|
作者：
Monteverde, Marta Lidia [1 ]
机构：
[1] Hosp Juan P Garraham, Jefa Clin, Nefrol, Buenos Aires, Argentina
来源：
REVISTA DE NEFROLOGIA DIALISIS Y TRASPLANTE | 2023年 / 43卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：197 / 198
页数：2
相关论文
共 50 条
  • [21] Hypothyroidism in primary hyperoxaluria type 1
    Frishberg, Y
    Feinstein, S
    Rinat, C
    Drukker, A
    JOURNAL OF PEDIATRICS, 2000, 136 (02): : 255 - 257
  • [22] Primary hyperoxaluria type 1 in japan
    Takayama, T
    Nagata, M
    Ichiyama, A
    Ozono, S
    AMERICAN JOURNAL OF NEPHROLOGY, 2005, 25 (03) : 297 - 302
  • [23] Primary hyperoxaluria type 1 in Japan
    Ichiyama, A
    Oda, T
    Maeda-Nakai, E
    CELL BIOCHEMISTRY AND BIOPHYSICS, 2000, 32 (1-3) : 171 - 176
  • [24] Primary hyperoxaluria type 1 in Japan
    Arata Ichiyama
    Toshiaki Oda
    Eiko Maeda-Nakai
    Cell Biochemistry and Biophysics, 2000, 32 : 171 - 176
  • [25] Concomitant Treatment With Lumasiran and Nedosiran in a Child With Primary Hyperoxaluria Type 1
    Braekman, Eline
    Raes, Ann
    De Bruyne, Ruth
    Verloo, Patrick
    Prytula, Agnieszka
    KIDNEY INTERNATIONAL REPORTS, 2025, 10 (02): : 620 - 621
  • [26] Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1
    Hoppe, B.
    Beck, B.
    Gatter, N.
    von Unruh, G.
    Tischer, A.
    Hesse, A.
    Laube, N.
    Kaul, P.
    Sidhu, H.
    KIDNEY INTERNATIONAL, 2006, 70 (07) : 1305 - 1311
  • [27] Treatment options in primary hyperoxaluria Type I
    Cellini, Barbara
    EXPERT OPINION ON ORPHAN DRUGS, 2017, 5 (04): : 309 - 319
  • [28] TREATMENT OF TYPE-I PRIMARY HYPEROXALURIA
    GERSHOFF, SN
    NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (15): : 959 - 959
  • [29] Lumasiran: expanding the treatment options for patients with primary hyperoxaluria type 1
    Hulton, Sally-Anne
    EXPERT OPINION ON ORPHAN DRUGS, 2021, 9 (7-10): : 189 - 198
  • [30] Safety and Efficacy Study of Lumasiran (ALN-GO1), an Investigational RNA Interference (RNAi) Therapeutic, in Patients with Primary Hyperoxaluria Type 1
    Mcgregor, Tracy
    Hulton, Sally
    Frishberg, Yaacov
    Deschenes, Georges
    Cochat, Pierre
    Magen, Daniella
    Harambat, Jerome
    Van't Hoff, William
    Hoppe, Bernd
    Lieske, John
    Haslett, Patrick
    Erbe, David
    Milliner, Dawn
    SWISS MEDICAL WEEKLY, 2018, 148 : 7S - 7S
12345